Palvella Therapeutics (PVLA) vs UroGen Pharma (URGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
UroGen Pharma (URGN) has outperformed Palvella Therapeutics (PVLA) over the past year, gaining 113.4% versus a gain of 75.5%. Over five years, URGN leads with a +117.3% price change compared with -63.6% for PVLA. Palvella Therapeutics is the larger company by market cap ($2.00 billion vs $1.82 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PVLA | URGN |
|---|---|---|
| Share price | $138.76 | $37.22 |
| Market cap | $2.00B | $1.82B |
| 1-day change | +5.65% | +0.65% |
| YTD return | +25.48% | +57.90% |
| 1-year return | +75.47% | +113.39% |
| 5-year return | -63.60% | +117.27% |
| Forward P/E | — | 13.32 |
| EPS (TTM) | $-4.85 | $-1.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $109.79M |
| Revenue growth (YoY) | — | +21.45% |
| Net income (latest FY) | $-41.72M | $-153.49M |
| Gross margin | — | 88.66% |
| Operating margin | — | -113.73% |
| Net margin | — | -139.81% |
| 52-week high | $161.38 | $50.81 |
| 52-week low | $65.93 | $15.86 |
| Distance from 52-week high | -14.02% | -26.75% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +66.14% | +61.20% |
| Average volume | 211.36K | 849.01K |
| Shares outstanding | 14.41M | 48.88M |
| Employees | 29 | 300 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- URGN has outperformed PVLA by 37.9 percentage points over the past year.
About Palvella Therapeutics
PVLA stock →Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About UroGen Pharma
URGN stock →UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 300 employees
PVLA vs URGN FAQ
Which is bigger, Palvella Therapeutics or UroGen Pharma?
Palvella Therapeutics (PVLA) is larger, with a market capitalization of $2.00B compared with $1.82B for UroGen Pharma (URGN).
Which stock has performed better over the past year, PVLA or URGN?
URGN returned +113.39% over the past 12 months, compared with +75.47% for PVLA (price return, excluding dividends). Past performance does not predict future results.
Are Palvella Therapeutics and UroGen Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.